Methenolone vs Oxandrolone
Methenolone (B-tier) vs Oxandrolone (S-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.
Methenolone — tier B
a non-17-alpha-alkylated androgen with a current Japanese oral acetate label, historical injectable enanthate use, and no validated systemic half-life for either formulation.
Japan's current oral acetate label supplies a real foreign medical record, while the missing human PK and modern organ-safety file keep the evidence below top tier.
0 validated systemic half-life studies located · half-life unknown; no qualifying systemic plasma half-life located for acetate or enanthate · androgens
Oxandrolone — tier S
an oral 17-alpha-alkylated androgen with measured human pharmacokinetics and controlled burn data, whose US approvals were withdrawn in 2023 after FDA safety and effectiveness review.
the burn outcome and human half-life are real, and so are the withdrawal, boxed liver warning, lipid injury, and endocrine risks.
31.6 vs 43.3 days hospital stay in one severe-burn RCT · half-life 10.4 hours in younger volunteers and 13.3 hours in older adults in the historical Oxandrin label · androgens
at a glance
- Methenolone: tier B · 0 validated systemic half-life studies located
- Oxandrolone: tier S · 31.6 vs 43.3 days hospital stay in one severe-burn RCT
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
